Candriam Luxembourg S.C.A. held its stake in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 214,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Candriam Luxembourg S.C.A. owned approximately 0.57% of OncoMed Pharmaceuticals worth $713,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of OMED. American International Group Inc. boosted its stake in OncoMed Pharmaceuticals by 9.0% in the first quarter. American International Group Inc. now owns 10,977 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 905 shares during the last quarter. KCG Holdings Inc. acquired a new stake in OncoMed Pharmaceuticals during the first quarter worth $103,000. Russell Investments Group Ltd. acquired a new stake in OncoMed Pharmaceuticals during the first quarter worth $141,000. Metropolitan Life Insurance Co. NY acquired a new stake in OncoMed Pharmaceuticals during the first quarter worth $160,000. Finally, Teachers Advisors LLC boosted its stake in OncoMed Pharmaceuticals by 10.8% in the fourth quarter. Teachers Advisors LLC now owns 30,423 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 2,961 shares during the last quarter. 44.18% of the stock is currently owned by institutional investors and hedge funds.
OncoMed Pharmaceuticals, Inc. (OMED) opened at 4.03 on Tuesday. The firm’s market capitalization is $151.65 million. The stock’s 50 day moving average is $3.54 and its 200-day moving average is $5.62. OncoMed Pharmaceuticals, Inc. has a 12 month low of $2.91 and a 12 month high of $12.58.
OncoMed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. The business had revenue of $6.20 million for the quarter, compared to the consensus estimate of $6.08 million. During the same quarter in the previous year, the business earned ($0.91) earnings per share. The firm’s revenue was down 7.0% on a year-over-year basis. Equities analysts anticipate that OncoMed Pharmaceuticals, Inc. will post ($1.85) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “OncoMed Pharmaceuticals, Inc. (OMED) Position Held by Candriam Luxembourg S.C.A.” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://stocknewstimes.com/2017/08/15/oncomed-pharmaceuticals-inc-omed-position-held-by-candriam-luxembourg-s-c-a.html.
OMED has been the topic of a number of analyst reports. HC Wainwright lowered their target price on shares of OncoMed Pharmaceuticals from $9.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, May 15th. Jefferies Group LLC reissued a “buy” rating and issued a $5.00 target price on shares of OncoMed Pharmaceuticals in a research note on Sunday, July 9th. Piper Jaffray Companies set a $5.00 target price on shares of OncoMed Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, July 10th. SunTrust Banks, Inc. cut shares of OncoMed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, April 17th. Finally, Cantor Fitzgerald set a $6.00 price objective on shares of OncoMed Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, May 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company. OncoMed Pharmaceuticals has an average rating of “Hold” and an average target price of $8.00.
In other OncoMed Pharmaceuticals news, Director Jonathan D. Root sold 13,880 shares of the stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $3.71, for a total transaction of $51,494.80. Following the transaction, the director now directly owns 121,020 shares in the company, valued at $448,984.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jonathan D. Root sold 7,487 shares of the stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $3.70, for a total transaction of $27,701.90. Following the transaction, the director now owns 121,020 shares in the company, valued at $447,774. The disclosure for this sale can be found here. Insiders have acquired 64,614 shares of company stock worth $222,249 over the last quarter. Company insiders own 32.80% of the company’s stock.
OncoMed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
